Its potent renal protective effects in SA-AKI suggest that targeting class IIa HDACs could serve as a novel therapeutic strategy for treating SA-AKI, while potentially avoiding the unintended adverse effects associated with pan-HDAC inhibitors. The gene discussed is HDAC9; the disease is acute kidney injury.